Overall rank by patents
#48,059
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Kandy Therapeutics Limited
USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
5
Total patents granted
4
CPC technology areas
30.6
Avg claims per patent
-
5-year filing velocity
The verdict
Kandy holds 5 US patents across 4 technology areas, rank #48,059 of 50,000 tracked assignees.
- #48,059
- of 50,000 US assignees by volume
- Top 17%
- by Innovation Score (48.3/100)
- 30.6
- avg claims per patent
Portfolio overview
Kandy Therapeutics Limited has been granted 5 US utility patents between 2020 and 2025, placing Kandy Therapeutics Limited at rank #48,059 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 30.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Kandy Therapeutics Limited is one of the more focused assignees in the PatentsView dataset. By volume, Kandy sits between KACI Intermodal Systems, Llc (5 patents, rank #48,055) and Kanken Techno Co., Ltd. (5 patents, rank #48,063) - the closest US assignees by grant volume. The composite Innovation Score of 48.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Kandy Therapeutics Limited's 30.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Kandy Therapeutics Limited against peers pursuing similar technology classes.
Who files at Kandy's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- KACI Intermodal S…
KACI INTERMODAL SYSTEMS, LLC
5 patents
- Kaeco Group
KAECO Group, Inc.
5 patents
- Kaken TECH
KAKEN TECH CO., LTD.
5 patents
- Kalita
KALITA CO., LTD.
5 patents
- Kangwon National…
KANGWON NATIONAL UNIVERSITY INDUSTRY COOPERATION FOUNDATION
5 patents
- Kangyue Technology
KANGYUE TECHNOLOGY CO., LTD.
5 patents
- Kankakee Spikeball
KANKAKEE SPIKEBALL, INC.
5 patents
- Kanken Techno
KANKEN TECHNO CO., LTD.
5 patents
- Kandy Therapeutics ◀
KANDY THERAPEUTICS LIMITED
5 patents
What this shows Kandy holds 5 patents at rank #48,059, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Kandy
By rank, the assignees closest to #48,059 in granted patent volume.
- KACI Intermodal Systems, Llc #48,055 · 5 patents
- Kaeco Group, Inc. #48,056 · 5 patents
- Kaken TECH Co., Ltd. #48,057 · 5 patents
- Kalita Co., Ltd. #48,058 · 5 patents
- Kangwon National University Industry Cooperation Foundation #48,060 · 5 patents
- Kangyue Technology Co., Ltd. #48,061 · 5 patents
- Kankakee Spikeball, Inc. #48,062 · 5 patents
- Kanken Techno Co., Ltd. #48,063 · 5 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Kandy's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Kandy's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
48 Top 17% higher than 83% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 20.0% |
| 2023 | 3 | 60.0% |
| 2025 | 1 | 20.0% |
Which technologies does Kandy Therapeutics Limited patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Frequently Asked Questions
How many patents does Kandy Therapeutics Limited hold?
Kandy Therapeutics Limited holds 5 US granted patents filed between 2020 and 2025, spanning 4 technology areas.
What is Kandy Therapeutics Limited's Innovation Score?
Kandy Therapeutics Limited has an Innovation Score of 48.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Kandy Therapeutics Limited focus on?
Kandy Therapeutics Limited's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 5 patents. The company has filed patents in 4 CPC subclasses total.
Is Kandy Therapeutics Limited's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Kandy Therapeutics Limited.
What does claim depth mean for Kandy Therapeutics Limited's patents?
Kandy Therapeutics Limited's patents average 30.6 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Kandy Therapeutics Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Kandy's 5 grants land it in the top 17% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Kandy ranks #48,059 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.